Rosuvastatin safety and efficacy in coronary heart disease patients
Aim. To study rosuvastatin safety and effects on lipid profile (LP) in coronary heart disease (CHD) patients. Material and methods. The study included 30 males (mean age 57±9 years) with diagnosed CHD, Functional Class II-III stable effort angina, receiving adequate basic therapy. In all participant...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2006-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250464526237696 |
|---|---|
| author | I. V. Sergienko M. V. Ezhov V. P. Masenko |
| author_facet | I. V. Sergienko M. V. Ezhov V. P. Masenko |
| author_sort | I. V. Sergienko |
| collection | DOAJ |
| description | Aim. To study rosuvastatin safety and effects on lipid profile (LP) in coronary heart disease (CHD) patients. Material and methods. The study included 30 males (mean age 57±9 years) with diagnosed CHD, Functional Class II-III stable effort angina, receiving adequate basic therapy. In all participants, initial total cholesterol (TCH) level was >5,2 mmol/l. At baseline and after three weeks of rosuvastatin therapy (10 mg/d), general and biochemical blood assays were performed, to measure LP, AST, ALT, creatine kinase (CK), glucose, total bilirubin (BR) and creatinine levels. Results. Three-month rosuvastatin therapy improved blood LP: TCH, triglyceride (TG) and low-density lipoprotein CH (LDL-CH) levels significantly reduced, and high-density lipoprotein CH (HDL-CH) level increased. In general, levels of TCH decreased by 31%, TG – by 39%, LDL-CH – by 44%, and HDL-CH level increased by 6%. Target TCH level was achieved in 17 participants (57%), and target LDL-CH level – in 23 patients (77%). Throughout the study, no adverse reactions (hepatic enzymes, CK, BR, or glucose level increase) were observed. Conclusion. Rosuvastatin did not increase rhabdomyolysis or myopathy risk. Rosuvastatin therapy helped to achieve significant decrease in TCH and LDL-CH levels. |
| format | Article |
| id | doaj-art-4fc8077ab4cd46c7ad82876eed6e4c62 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2006-10-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-4fc8077ab4cd46c7ad82876eed6e4c622025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252006-10-015527311002Rosuvastatin safety and efficacy in coronary heart disease patientsI. V. Sergienko0M. V. Ezhov1V. P. Masenko2Russian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development. MoscowRussian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development. MoscowRussian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development. MoscowAim. To study rosuvastatin safety and effects on lipid profile (LP) in coronary heart disease (CHD) patients. Material and methods. The study included 30 males (mean age 57±9 years) with diagnosed CHD, Functional Class II-III stable effort angina, receiving adequate basic therapy. In all participants, initial total cholesterol (TCH) level was >5,2 mmol/l. At baseline and after three weeks of rosuvastatin therapy (10 mg/d), general and biochemical blood assays were performed, to measure LP, AST, ALT, creatine kinase (CK), glucose, total bilirubin (BR) and creatinine levels. Results. Three-month rosuvastatin therapy improved blood LP: TCH, triglyceride (TG) and low-density lipoprotein CH (LDL-CH) levels significantly reduced, and high-density lipoprotein CH (HDL-CH) level increased. In general, levels of TCH decreased by 31%, TG – by 39%, LDL-CH – by 44%, and HDL-CH level increased by 6%. Target TCH level was achieved in 17 participants (57%), and target LDL-CH level – in 23 patients (77%). Throughout the study, no adverse reactions (hepatic enzymes, CK, BR, or glucose level increase) were observed. Conclusion. Rosuvastatin did not increase rhabdomyolysis or myopathy risk. Rosuvastatin therapy helped to achieve significant decrease in TCH and LDL-CH levels.https://cardiovascular.elpub.ru/jour/article/view/1292hyperlipidemiastatinsrosuvastatincoronary heart disease |
| spellingShingle | I. V. Sergienko M. V. Ezhov V. P. Masenko Rosuvastatin safety and efficacy in coronary heart disease patients Кардиоваскулярная терапия и профилактика hyperlipidemia statins rosuvastatin coronary heart disease |
| title | Rosuvastatin safety and efficacy in coronary heart disease patients |
| title_full | Rosuvastatin safety and efficacy in coronary heart disease patients |
| title_fullStr | Rosuvastatin safety and efficacy in coronary heart disease patients |
| title_full_unstemmed | Rosuvastatin safety and efficacy in coronary heart disease patients |
| title_short | Rosuvastatin safety and efficacy in coronary heart disease patients |
| title_sort | rosuvastatin safety and efficacy in coronary heart disease patients |
| topic | hyperlipidemia statins rosuvastatin coronary heart disease |
| url | https://cardiovascular.elpub.ru/jour/article/view/1292 |
| work_keys_str_mv | AT ivsergienko rosuvastatinsafetyandefficacyincoronaryheartdiseasepatients AT mvezhov rosuvastatinsafetyandefficacyincoronaryheartdiseasepatients AT vpmasenko rosuvastatinsafetyandefficacyincoronaryheartdiseasepatients |